Michel Vounatsos in 2017, the year he became Biogen CEO (Dina Rudick/The Boston Globe via Getty Images)
May 3, 2022 07:32 AM EDTUpdated 08:57 AM
People
R&D

Michel Vounatsos is on his way out as Bio­gen shut­ters Aduhelm ef­fort and launch­es pipeline re­org

John Carroll

Editor & Founder

Stymied by Medicare and forced to ad­mit the end of its once sky-high hopes in the con­tro­ver­sial Alzheimer’s med­i­cine Aduhelm, Bio­gen an­nounced this morn­ing that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

A service from the Financial Times